As observed for combinations of costimulatory mAbs, the OX40L and 4-1BBL dual costimulation has been shown to be effective in reducing tumor growth and enhances mainly the CD8+ T-cell response (Weinberg et al., 2000; Cuadros et al., 2005; Lee et al., 2006; Gray et al., 2008; Redmond et al., 2009; Manrique-Rincón et al., 2017). The gene discussed is CD8A; the disease is neoplasm.